ID   sNF96.2
AC   CVCL_K281
SY   SNF96.2; sNF96-2
DR   ATCC; CRL-2884
DR   BioSample; SAMN03471810
DR   Cosmic; 1644553
DR   Wikidata; Q54955059
RX   PubMed=14762442;
RX   PubMed=17876295;
RX   PubMed=22346343;
RX   PubMed=28469964;
RX   PubMed=32076030;
RX   PubMed=32642732;
RX   PubMed=34059954;
RX   PubMed=36818284;
WW   Provider; UF Innovate; 11278; https://web.archive.org/web/20150905200621/http://technologylicensing.research.ufl.edu/technologies/11278_human-schwann-cell-like-cell-line-snf96-2
CC   Doubling time: ~33 hours (ATCC=CRL-2884).
CC   Karyotypic information: Average ploidy of 2.02 (PubMed=36818284).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=34059954).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=34059954).
CC   Sequence variation: Gene deletion; HGNC; HGNC:7765; NF1; Zygosity=Heterozygous (PubMed=36818284).
CC   Sequence variation: Mutation; HGNC; HGNC:7765; NF1; Simple; p.Asn1229Metfs*11 (c.3683delC); Zygosity=Heterozygous; Note=Germline (PubMed=17876295).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Peripheral nervous system, lower leg nerve; UBERON=UBERON_0004218.
CC   Cell type: Schwann cell; CL=CL_0002573.
ST   Source(s): ATCC=CRL-2884; PubMed=32076030; PubMed=36818284
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10
ST   D16S539: 11
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 30
ST   D2S1338: 17
ST   D3S1358: 16 (ATCC=CRL-2884; PubMed=36818284)
ST   D3S1358: 16,21 (PubMed=32076030)
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 22
ST   Penta D: 14
ST   Penta E: 15
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 17,19 (ATCC=CRL-2884; PubMed=36818284)
ST   vWA: 17,19,20 (PubMed=32076030)
DI   NCIt; C3798; Malignant peripheral nerve sheath tumor
DI   NCIt; C3273; Neurofibromatosis type 1
DI   ORDO; Orphanet_3148; Malignant peripheral nerve sheath tumor
DI   ORDO; Orphanet_636; Neurofibromatosis type 1
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   27Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 10-04-25; Version: 22
//
RX   PubMed=14762442; DOI=10.1038/sj.onc.1207068;
RA   Li Y.-W., Rao P.K., Wen R., Song Y., Muir D.F. 4th, Wallace M.R.,
RA   van Horne S.J., Tennekoon G.I., Kadesch T.;
RT   "Notch and Schwann cell transformation.";
RL   Oncogene 23:1146-1152(2004).
//
RX   PubMed=17876295; DOI=10.1038/labinvest.3700675;
RA   Perrin G.Q., Li H., Fishbein L., Thomson S.A., Hwang M.S.,
RA   Scarborough M.T., Yachnis A.T., Wallace M.R., Mareci T.H., Muir D.F. 4th;
RT   "An orthotopic xenograft model of intraneural NF1 MPNST suggests a
RT   potential association between steroid hormones and tumor cell
RT   proliferation.";
RL   Lab. Invest. 87:1092-1102(2007).
//
RX   PubMed=22346343; DOI=10.4137/TOG.S8830; PMCID=PMC3273949;
RA   Sun D., Tainsky M.A., Haddad R.;
RT   "Oncogene mutation survey in MPNST cell lines enhances the dominant
RT   role of hyperactive Ras in NF1 associated pro-survival and
RT   malignancy.";
RL   Transl. Oncogenomics 5:1-7(2012).
//
RX   PubMed=28469964; PMCID=PMC5411799;
RA   Guo J.-M., Grovola M.R., Xie H., Coggins G.E., Duggan P., Hasan R.,
RA   Huang J.-L., Lin D.W., Song C., Witek G.M., Berritt S., Schultz D.C.,
RA   Field J.;
RT   "Comprehensive pharmacological profiling of neurofibromatosis cell
RT   lines.";
RL   Am. J. Cancer Res. 7:923-934(2017).
//
RX   PubMed=32076030; DOI=10.1038/s41598-020-59789-4; PMCID=PMC7031337;
RA   Amirnasr A., Verdijk R.M., van Kuijk P.F., Kartal P., Vriends A.L.M.,
RA   French P.J., van Royen M.E., Taal W., Sleijfer S., Wiemer E.A.C.;
RT   "Deregulated microRNAs in neurofibromatosis type 1 derived malignant
RT   peripheral nerve sheath tumors.";
RL   Sci. Rep. 10:2927.1-2927.14(2020).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049; PMCID=PMC7317054;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:i50-i61(2020).
//
RX   PubMed=34059954; DOI=10.1007/s00439-021-02296-x;
RA   Magallon-Lorenz M., Fernandez-Rodriguez J., Terribas E.,
RA   Creus-Bachiller E., Romagosa C., Estival A., Perez Sidelnikova D.,
RA   Salvador H., Villanueva A., Blanco I., Carrio M., Lazaro C., Serra E.,
RA   Gel B.;
RT   "Chromosomal translocations inactivating CDKN2A support a single path
RT   for malignant peripheral nerve sheath tumor initiation.";
RL   Hum. Genet. 140:1241-1252(2021).
//
RX   PubMed=36818284; DOI=10.1016/j.isci.2023.106096; PMCID=PMC9929861;
RA   Magallon-Lorenz M., Terribas E., Ortega-Bertran S., Creus-Bachiller E.,
RA   Fernandez M., Requena G., Rosas I., Mazuelas H., Uriarte-Arrazola I.,
RA   Negro A., Lausova T., Castellanos E., Blanco I., DeVries G.H.,
RA   Kawashima H., Legius E., Brems H., Mautner V.-F., Kluwe L., Ratner N.,
RA   Wallace M.R., Fernandez-Rodriguez J., Lazaro C., Fletcher J.A.,
RA   Reuss D.E., Carrio M., Gel B., Serra E.;
RT   "Deep genomic analysis of malignant peripheral nerve sheath tumor cell
RT   lines challenges current malignant peripheral nerve sheath tumor
RT   diagnosis.";
RL   iScience 26:106096.1-106096.22(2023).
//